{"id":745152,"date":"2015-07-28T05:30:00","date_gmt":"2015-07-28T05:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/"},"modified":"2025-11-07T01:25:03","modified_gmt":"2025-11-07T06:25:03","slug":"merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/","title":{"rendered":"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection"},"content":{"rendered":"<p class=\"bwalignc\">       Company Granted FDA Priority Review with Target Action Date of        January 28, 2016     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for review the New Drug Application for grazoprevir\/elbasvir<br \/>\n      (100mg\/50mg), an investigational, once-daily, single-tablet combination<br \/>\n      therapy for the treatment of adult patients infected with chronic<br \/>\n      hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6.<sup>1<\/sup> The FDA<br \/>\n      granted Priority Review for grazoprevir\/elbasvir (100mg\/50mg), with a<br \/>\n      Prescription Drug User Fee Act (PDUFA) action date of January 28, 2016.\n    <\/p>\n<p>\n      \u201cThe U.S. FDA\u2019s Priority Review designation for grazoprevir\/elbasvir<br \/>\n      underscores how innovative treatment approaches for chronic hepatitis C<br \/>\n      are still needed for many patient populations,\u201d said Dr. Roy Baynes,<br \/>\n      senior vice president of clinical development, Merck Research<br \/>\n      Laboratories. \u201cOur clinical data for grazoprevir\/elbasvir in broad and<br \/>\n      diverse patient populations with chronic hepatitis C are very<br \/>\n      encouraging, and we look forward to continuing our dialogue with the FDA<br \/>\n      to bring this novel combination medicine to the appropriate patients<br \/>\n      with chronic hepatitis C.\u201d\n    <\/p>\n<p>\n      The New Drug Application for grazoprevir\/elbasvir (100mg\/50mg) is based<br \/>\n      in part upon data from the pivotal&nbsp;<i>C-EDGE<\/i>&nbsp;clinical trials<br \/>\n      program, as well as the&nbsp;<i>C-SURFER<\/i>&nbsp;and&nbsp;<i>C-SALVAGE<\/i>&nbsp;trials.<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fhepatitis_c-infocenter&amp;esheet=51150351&amp;newsitemid=20150728005530&amp;lan=en-US&amp;anchor=Data+from+these+trials&amp;index=1&amp;md5=24988d1582b4bec433d6d09928545ceb\" rel=\"nofollow\">Data<br \/>\n      from these trials<\/a> were previously presented at The International<br \/>\n      Liver Conference 2015\u2122. Collectively, these trials evaluated treatment<br \/>\n      regimens of grazoprevir\/elbasvir (100mg\/50mg), with or without<br \/>\n      ribavirin, in multiple genotypes (GT1, 4 and 6) including patient<br \/>\n      populations who were previously treated, and those with cirrhosis or<br \/>\n      certain co-morbidities (e.g., HIV\/HCV co-infection, chronic kidney<br \/>\n      disease stages 4 and 5).\n    <\/p>\n<p>\n      <b>About Grazoprevir\/Elbasvir<\/b>\n    <\/p>\n<p>\n      Grazoprevir\/elbasvir is Merck\u2019s investigational, once-daily,<br \/>\n      single-tablet combination therapy consisting of grazoprevir (NS3\/4A<br \/>\n      protease inhibitor) and elbasvir (NS5A replication complex inhibitor).<br \/>\n      As part of Merck\u2019s broad clinical trials program, grazoprevir\/elbasvir<br \/>\n      is being evaluated in multiple HCV genotypes including patients with<br \/>\n      difficult-to-treat conditions such as HIV\/HCV co-infection, advanced<br \/>\n      chronic kidney disease, inherited blood disorders, liver cirrhosis and<br \/>\n      those on opiate substitution therapy.\n    <\/p>\n<p>\n      In April 2015, the FDA granted Breakthrough Therapy designation status<br \/>\n      for grazoprevir\/elbasvir for the treatment of patients infected with<br \/>\n      chronic HCV GT1 with end stage renal disease on hemodialysis, and<br \/>\n      Breakthrough Therapy designation status for grazoprevir\/elbasvir for the<br \/>\n      treatment of patients infected with chronic HCV GT4. Breakthrough<br \/>\n      Therapy designation is intended to expedite the development and review<br \/>\n      of a candidate that is planned for use, alone or in combination, to<br \/>\n      treat a serious or life-threatening disease or condition when<br \/>\n      preliminary clinical evidence indicates that the drug may demonstrate<br \/>\n      substantial improvement over existing therapies on one or more<br \/>\n      clinically significant endpoints.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51150351&amp;newsitemid=20150728005530&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=277a4e3115278d96441bba48c96c1ef3\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51150351&amp;newsitemid=20150728005530&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=dc30e2ac6edd0a01ab0c51c6f8580926\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51150351&amp;newsitemid=20150728005530&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=fb71863bdcfecc86ed9d354775ea6258\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51150351&amp;newsitemid=20150728005530&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=3c5d220280ec9b8da1595d45d30f3787\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co. Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51150351&amp;newsitemid=20150728005530&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=c588ccec1ed0b178b44d3fdb84b31950\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Grazoprevir is an HCV NS3\/4A protease inhibitor and<br \/>\n      elbasvir is an HCV NS5A replication complex inhibitor\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150728005530r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, (908) 246-5701<br \/>Sarra Herzog, (201)        669-6570<br \/>or<br \/>Investor:<br \/>Joe Romanelli, (908) 740-1986<br \/>Justin        Holko, (908) 740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for grazoprevir\/elbasvir (100mg\/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients infected with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6. 1 The FDA granted Priority Review for grazoprevir\/elbasvir (100mg\/50mg), with a Prescription Drug User Fee Act (PDUFA) action date of January 28, 2016. \u201cThe U.S. FDA\u2019s Priority Review designation for grazoprevir\/elbasvir underscores how innovative treatment approaches for chronic hepatitis C are still needed for many patient populations,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cOur clinical data for grazoprevir\/elbasvir in broad and diverse patient populations with chronic hepatitis C are very encouraging, and we look forward to continuing<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745152","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for grazoprevir\/elbasvir (100mg\/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients infected with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6. 1 The FDA granted Priority Review for grazoprevir\/elbasvir (100mg\/50mg), with a Prescription Drug User Fee Act (PDUFA) action date of January 28, 2016. \u201cThe U.S. FDA\u2019s Priority Review designation for grazoprevir\/elbasvir underscores how innovative treatment approaches for chronic hepatitis C are still needed for many patient populations,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cOur clinical data for grazoprevir\/elbasvir in broad and diverse patient populations with chronic hepatitis C are very encouraging, and we look forward to continuing\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\\\/\",\"name\":\"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\\\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-07-28T05:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\\\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for grazoprevir\/elbasvir (100mg\/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients infected with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6. 1 The FDA granted Priority Review for grazoprevir\/elbasvir (100mg\/50mg), with a Prescription Drug User Fee Act (PDUFA) action date of January 28, 2016. \u201cThe U.S. FDA\u2019s Priority Review designation for grazoprevir\/elbasvir underscores how innovative treatment approaches for chronic hepatitis C are still needed for many patient populations,\u201d said Dr. Roy Baynes, senior vice president of clinical development, Merck Research Laboratories. \u201cOur clinical data for grazoprevir\/elbasvir in broad and diverse patient populations with chronic hepatitis C are very encouraging, and we look forward to continuing","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:03+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/","name":"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-07-28T05:30:00+00:00","dateModified":"2025-11-07T06:25:03+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-food-and-drug-administration-acceptance-of-new-drug-application-for-grazoprevir-elbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir\/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"49b2e4d6-e543-4f9b-b40a-08726971aded","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-US-Food-and-Drug-Administration-Acceptance-of-New-Drug-Application-for-GrazoprevirElbasvir-an-Investigational-Therapy-6WQCQ.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745152\/revisions"}],"predecessor-version":[{"id":3674618,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745152\/revisions\/3674618"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745152"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}